Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ® HPV assay

Halfon, Philippe; Benmoura, D.; Agostini, Aubert; Khiri, Hacène; Martineau, Agnès; Pénaranda, Guillaume; Blanc, B.

doi:10.1016/j.jcv.2009.11.011

Cited by 38 publications

(50 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, the specificity was higher in ASC-US than in H-SIL, both for HPV DNA and mRNA. This phenomenon has been reported by other studies (20,22,30,38). This association makes it not reasonable to present estimates for the overall specificity.…”

Section: Discussionmentioning

confidence: 57%

“…Commercially available robust assays for HPV mRNA detection can be performed in reflex after liquid based cytology or the HPV DNA test (4,9,22,26,28,30,33,38). We compared here the clinical performance of the PreTect HPVProofer E6/E7 mRNA assay (Norchip, Klokkarstua, Norway) as a triage test to that of the HPV DNA test and cytology for detecting high-grade cervical intraepithelial neoplasia or worse (CIN2ϩ).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Sensitivity, Specificity, and Clinical Value of Human Papillomavirus (HPV) E6/E7 mRNA Assay as a Triage Test for Cervical Cytology and HPV DNA Test

Benevolo¹,

Vocaturo²,

Caraceni

et al. 2011

J Clin Microbiol

111

View full text Add to dashboard Cite

There is evidence that testing for human papillomavirus (HPV) E6/E7 mRNA is more specific than testing for HPV DNA. A retrospective study was carried out to evaluate the performance of the PreTect HPV-Proofer E6/E7 mRNA assay (Norchip) as a triage test for cytology and HPV DNA testing. This study analyzed 1,201 women, 688 of whom had a colposcopy follow-up and 195 of whom had histology-confirmed high-grade intraepithelial neoplasia or worse (CIN2؉). The proportion of positive results and the sensitivity and specificity for CIN2؉ were determined for HPV mRNA in comparison to HPV DNA and cytology. All data were adjusted for follow-up completeness. Stratified by cytological grades, the HPV mRNA sensitivity was 83% (95% confidence interval [CI] ‫؍‬ 63 to 94%) in ASC-US (atypical squamous cells of undetermined significance), 62% (95% CI ‫؍‬ 47 to 75%) in L-SIL (low-grade squamous intraepithelial lesion), and 67% (95% CI ‫؍‬ 57 to 76%) in H-SIL (high-grade squamous intraepithelial lesion). The corresponding figures were 99, 91, and 96%, respectively, for HPV DNA. The specificities were 82, 76, and 45%, respectively, for HPV mRNA and 29, 13, and 4%, respectively, for HPV DNA. Used as a triage test for ASC-US and L-SIL, mRNA reduced colposcopies by 79% (95% CI ‫؍‬ 74 to 83%) and 69% (95% CI ‫؍‬ 65 to 74%), respectively, while HPV DNA reduced colposcopies by 38% (95% CI ‫؍‬ 32 to 44%) and by 15% (95% CI ‫؍‬ 12 to 19%), respectively. As a HPV DNA positivity triage test, mRNA reduced colposcopies by 63% (95% CI ‫؍‬ 60 to 66%), having 68% sensitivity (95% CI ‫؍‬ 61 to 75%), whereas cytology at the ASC-US؉ threshold reduced colposcopies by 23% (95% CI ‫؍‬ 20 to 26%), showing 92% sensitivity (95% CI ‫؍‬ 87 to 95%). In conclusion, PreTect HPV-Proofer mRNA can serve as a better triage test than HPV DNA to reduce colposcopy referral in both ASC-US and L-SIL. It is also more efficient than cytology for the triage of HPV DNA-positive women. Nevertheless, its low sensitivity demands a strict follow-up of HPV DNA positive-mRNA negative cases.

show abstract

Section: Discussionmentioning

confidence: 57%

mentioning

confidence: 99%

Sensitivity, Specificity, and Clinical Value of Human Papillomavirus (HPV) E6/E7 mRNA Assay as a Triage Test for Cervical Cytology and HPV DNA Test

Benevolo¹,

Vocaturo²,

Caraceni

et al. 2011

J Clin Microbiol

111

View full text Add to dashboard Cite

show abstract

“…In a comparative study of three HPV assays performed on 140 women referred for colposcopy and histology, NucliSENS showed significantly lower clinical sensitivity for the detection of CIN2+ or HSIL in comparison with hc2 and Linear Array (76 vs 95% and 92%, respectively), but had a significantly higher clinical specificity (63 vs 49% and 45%, respectively) [101].…”

Section: Nuclisens Easyq Hpvmentioning

confidence: 94%

“…Several comparative evaluations of Linear Array with other HPV assays have been published in peer-reviewed journals and, in addition, the assay has been frequently used in discordant analyses [37,55,68,86,[96][97][98][99][100][101]. In the largest comparative study, which [86].…”

Section: Linear Array Hpv Genotyping Testmentioning

confidence: 99%

Commercially available assays for multiplex detection of alpha human papillomaviruses

Poljak

Kocjan

2010

Expert Review of Anti-infective Therapy

115

129

View full text Add to dashboard Cite

“…In short, 5 μL of DNA/RNA extract was submitted to NASBA. Six different molecular probes able to detect HPV 16, 18, 31, 33, 45 types and U1A ribonucleoprotein (internal reaction control) were used (19) . The multiplex detection was developed with two fluorescent dyes: 6-carboxy-fluorescein (6-FAM) for 16, 31 and 33, 6-carboxy-X-rhodamine (6-ROX) HPV types for internal control and HPV 18 and 45 types.…”

Section: Nasba (Nucleic Acid-sequence Based Amplification Assay Biommentioning

confidence: 99%

CerviCal Cytology, HPv DNa aND mrNa – a ComParative StuDy iN 162 PatieNtS

Martins¹

2012

J bras doenças sex transm

View full text Add to dashboard Cite

Introduction: in contrast to the general improvement of the socioeconomic status of the Brazilian population, pathologies that are characteristic of poor health assistance persist. Among those, cervical cancer (CC) is emblematic; it still presents a persistently high incidence. Objective: to compare the performance of cervical cytology to HPV DNA and mRNA detection methods in 162 patients undergoing routine gynecological clinical practice. Methods: a total of 162 patients attended during routine gynecological examination in a private clinic in Florianópolis, Santa Catarina, Brazil, had cervical samples collected and processed for cytopathological and molecular tests, conventional PCR and NASBA. Positive samples positive for HPV DNA were submitted to Type-Specific PCR (TS-HPV PCR). Patients with altered smears were submitted to colposcopy and biopsy. Results: among the 162 samples, 19.8% (32/162) had altered smears, being 4/32 classified as ASC-H, 9/32 as ASC-US, 9/32 as LSIL and 10/32 as HSIL. Biopsies revealed nine cases of CIN I, nine CIN II and one CIN III, while seven were negative for cervical neoplasia. Overall, HPV DNA was detected in 38.3% (62/162) of the samples and HPV E6/E7 mRNA expression was found in 13.6% (22/162). Using TS-HPV PCR, HPV 16 was the most frequent type, found in 8% of the samples (5/62). Considering CIN2+ the gold-standard, cytology had 38.5% of specificity. Sensitivity and specificity of HPV-DNA PCR and NASBA were, respectively, 100% and 60%; 18.7% and 68.7%. Conclusion: mRNA E6/E7 expression was not a highly specific or sensitive marker for prevalent cervical disease while HPV DNA may be used for cervical cancer screening only in conjunction to more specific adjuvant tests.

show abstract

Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ® HPV assay

Cited by 38 publications

References 22 publications

Sensitivity, Specificity, and Clinical Value of Human Papillomavirus (HPV) E6/E7 mRNA Assay as a Triage Test for Cervical Cytology and HPV DNA Test

Sensitivity, Specificity, and Clinical Value of Human Papillomavirus (HPV) E6/E7 mRNA Assay as a Triage Test for Cervical Cytology and HPV DNA Test

Commercially available assays for multiplex detection of alpha human papillomaviruses

CerviCal Cytology, HPv DNa aND mrNa – a ComParative StuDy iN 162 PatieNtS

Contact Info

Product

Resources

About